GW Pharmaceuticals plc: 02/08/2016 GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016

Tickers: GWPH
August 2, 2016

GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016

LONDON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 August, 2016 its third quarter financial results for the period ending 30 June, 2016. GW will also host a conference call the same day at 8:30 a.m. EDT (1:30 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, LGS and Tuberous Sclerosis Complex. GW successfully commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc

Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway

+44 20 3727 1000

FleishmanHillard (U.S. Media) Paddi Hurley / Adam Silverstein 212 453 2382 / 917 697 9313

GW Pharmaceuticals plc published this content on 02 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 August 2016 11:14:03 UTC.